Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
42 hedge funds and large institutions have $12.1M invested in Orexigen Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 13 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
22% more call options, than puts
Call options by funds: $651K | Put options by funds: $533K
18% less funds holding
Funds holding: 51 → 42 (-9)
31% less capital invested
Capital invested by funds: $17.6M → $12.1M (-$5.54M)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$286K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$223K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$120K |
| 4 |
VF
Virtu Financial
New York
|
+$72.5K |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$37.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$1.1M |
| 2 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$348K |
| 3 |
TI
Telemetry Investments
New York
|
-$204K |
| 4 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$192K |
| 5 |
OWIM
Old West Investment Management
Los Angeles,
California
|
-$64.8K |
OREX Hedge Fund Activity: Q3 2017 in Review
42 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q3 2017, worth a combined $12.1M — down 31% from $17.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of OREX and 5 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 12 added.
The largest buyer was Bank of America, adding an estimated $286K. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $1.1M sold.
- 42 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q3 2017, down from 51 in Q2 2017.
- Funds reported $12.1M of Orexigen Therapeutics, Inc. stock for Q3 2017, down 31% quarter-over-quarter.
- 5 funds opened new Orexigen Therapeutics, Inc. positions in Q3 2017 and 13 closed out, a net change of -8 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q3 2017 was Bank of America, an estimated $286K added.
- The largest Orexigen Therapeutics, Inc. seller in Q3 2017 was Foresite Capital Management III, an estimated $1.1M sold.
Based on aggregated 13F filings for Q3 2017.